Ortho Regenerative $ORTH Closes $3M Financing & Agreement With Global Industry Leading Medical Company. CEO States “I Know We Are In The Lead”

Have you ever torn a: ●  muscle ●  rotator cuff ●  meniscus ●  cartilage How about someone you know? Or a favourite athlete? We wouldn’t blame you if you thought the care and repair of these kinds of injuries is pretty standard and highly successful …. but you would be wrong.  There is a MASSIVE problem with surgery failure rates for each of these as follows: ●  Rotator Cuff  50-60% ●  Meniscus  20-40% ●  Cartilage  15-35% $ORTH believes it has found the solution to this multi-billion dollar problem thanks to its proprietary RESTORE technology platform which dramatically improves the success rate of orthopedic and sports medicine surgeries. In short, the technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.  This includes Wound Healing, Cartilage repair and Osteo-arthritis In layman’s terms, it means $ORTH has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body. Newly appointed CEO Philippe Deschamps States “I Know We Are In The Lead” For FDA Trials Into The Healing Of Tendons, Ligaments, Cartilage and Meniscus .. and he has plenty of reason to carry such confidence considering the following … 3RD PARTY VALIDATION -$ORTH AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL On February 7th, $ORTH announced it entered into a Material Transfer Agreement ("MTA") with an undisclosed, industry-leading, global strategic medical company for the exclusive use of their proprietary platelet-rich plasma ("PRP") system in Ortho's upcoming ORTHO-R rotator cuff tear ("RCT") repair, phase I/II U.S. clinical trial. The Strategic Company will provide the PRP system disposable kits for all enrolled patients in the study as well as technical and training support. $ORTH, in return, has provided the Strategic Company with a right of "first offer" to distribute ORTHO-R in combination with their proprietary PRP System. $ORTH IS ATTACKING AND IN THE LEAD OF A MULTI BILLION $$ OPPORTUNITY In terms of Soft Tissue Repair this is a massive market opportunity as follows: ROTATOR CUFF TEAR – SHOULDER DYSFUNCTION AND PAIN • 4m patients in the U.S. alone • 600,000 annual surgeries in the U.S. alone • $600m+ market opportunity MENISCUS TEAR – PAINFUL AND COMPROMISES KNEE FUNCTION • 1.2m surgeries annually in U.S. alone • $1bn+ market opportunity CARTILAGE LESIONS REPAIR – LESIONS CAUSE FRICTION AND PAIN • 1.2m detected lesions annually in U.S. alone • 120,000 surgeries and a lack of options • $1bn+ market opportunity Listen to this powerful interview with CEO Philippe Deschamps